Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Improving support for young biomedical scientists.

Alberts B, Hyman T, Pickett CL, Tilghman S, Varmus H.

Science. 2018 May 18;360(6390):716-718. doi: 10.1126/science.aar8405. No abstract available.

PMID:
29773737
2.

Phytochemicals: Current strategies for treating breast cancer.

Israel BB, Tilghman SL, Parker-Lemieux K, Payton-Stewart F.

Oncol Lett. 2018 May;15(5):7471-7478. doi: 10.3892/ol.2018.8304. Epub 2018 Mar 20. Review.

3.

Not just Salk.

Greider C, Hopkins N, Steitz J, Amon A, Asai D, Barres B, Bass B, Bassler B, Birgeneau R, Bjorkman P, Botchan M, Brugge J, Cech T, Colwell R, Craig N, deLange T, Eisen M, Gottesman S, Green R, Handelsman J, Kimble J, King MC, Lehmann R, Marder E, Mullins D, O'Shea E, Schmid S, Seydoux G, Spradling A, Storz G, Szostak J, Telesnitsky A, Tilghman S, Tjian R, Vale R, Wolberger C, Zakian V.

Science. 2017 Sep 15;357(6356):1105-1106. doi: 10.1126/science.aao6221. No abstract available.

PMID:
28912235
4.

Profile of Bruce M. Alberts, 2016 Lasker-Koshland Special Achievement Award in Medical Science Awardee.

Tilghman SM.

Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1439-1441. doi: 10.1073/pnas.1700685114. Epub 2017 Feb 6. No abstract available.

5.

Protein Kinase CK2 Expression Predicts Relapse Survival in ERα Dependent Breast Cancer, and Modulates ERα Expression in Vitro.

Williams MD, Nguyen T, Carriere PP, Tilghman SL, Williams C.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010036. doi: 10.3390/ijerph13010036.

6.

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.

Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams CC, Boué SM, Burow ME, Collins-Burow B, Hilliard A, Davidson AM, Tilghman SL.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010010. doi: 10.3390/ijerph13010010.

7.

Opinion: Addressing systemic problems in the biomedical research enterprise.

Alberts B, Kirschner MW, Tilghman S, Varmus H.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):1912-3. doi: 10.1073/pnas.1500969112. No abstract available.

8.

Twists and turns: a scientific journey.

Tilghman SM.

Annu Rev Cell Dev Biol. 2014;30:1-21. doi: 10.1146/annurev-cellbio-100913-013512.

PMID:
25288111
9.

Benzimidazoles diminish ERE transcriptional activity and cell growth in breast cancer cells.

Payton-Stewart F, Tilghman SL, Williams LG, Winfield LL.

Biochem Biophys Res Commun. 2014 Aug 8;450(4):1358-62. doi: 10.1016/j.bbrc.2014.06.130. Epub 2014 Jul 2.

10.

Rescuing US biomedical research from its systemic flaws.

Alberts B, Kirschner MW, Tilghman S, Varmus H.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5773-7. doi: 10.1073/pnas.1404402111. Epub 2014 Apr 14.

11.

Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.

Tilghman SL, Townley I, Zhong Q, Carriere PP, Zou J, Llopis SD, Preyan LC, Williams CC, Skripnikova E, Bratton MR, Zhang Q, Wang G.

Mol Cell Proteomics. 2013 Sep;12(9):2440-55. doi: 10.1074/mcp.M112.023861. Epub 2013 May 23.

12.

In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models.

Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J.

J Health Care Poor Underserved. 2013 Feb;24(1 Suppl):104-11. doi: 10.1353/hpu.2013.0047.

13.

Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer.

Tilghman SL, Rhodes LV, Bratton MR, Carriere P, Preyan LC, Boue SM, Vasaitis TS, McLachlan JA, Burow ME.

J Health Care Poor Underserved. 2013 Feb;24(1 Suppl):36-46. doi: 10.1353/hpu.2013.0036. Review.

14.

Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line.

Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME.

PLoS One. 2012;7(11):e49067. doi: 10.1371/journal.pone.0049067. Epub 2012 Nov 30.

15.

Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Rhodes LV, Tilghman SL, Boue SM, Wang S, Khalili H, Muir SE, Bratton MR, Zhang Q, Wang G, Burow ME, Collins-Burow BM.

Oncol Lett. 2012 Jan;3(1):163-171. Epub 2011 Oct 24.

16.

Gαo potentiates estrogen receptor α activity via the ERK signaling pathway.

Bratton MR, Antoon JW, Duong BN, Frigo DE, Tilghman S, Collins-Burow BM, Elliott S, Tang Y, Melnik LI, Lai L, Alam J, Beckman BS, Hill SM, Rowan BG, McLachlan JA, Burow ME.

J Endocrinol. 2012 Jul;214(1):45-54. doi: 10.1530/JOE-12-0097. Epub 2012 May 4.

17.

Endocrine disruptor regulation of microRNA expression in breast carcinoma cells.

Tilghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiese TE, Nephew KP, Burow ME.

PLoS One. 2012;7(3):e32754. doi: 10.1371/journal.pone.0032754. Epub 2012 Mar 5.

18.

Environmental signaling and reproduction: a comparative biological and chemical perspective.

McLachlan JA, Tilghman SL, Burow ME, Bratton MR.

Mol Cell Endocrinol. 2012 May 6;354(1-2):60-2. doi: 10.1016/j.mce.2011.11.028. Epub 2011 Dec 8. Review.

19.

Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.

Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME.

Exp Cell Res. 2011 Nov 1;317(18):2573-81. doi: 10.1016/j.yexcr.2011.08.016. Epub 2011 Aug 30.

20.
21.

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME.

Cancer Res. 2011 Jan 15;71(2):603-13. doi: 10.1158/0008-5472.CAN-10-3185. Epub 2010 Dec 1. Erratum in: Cancer Res. 2011 May 1;71(9):3432.

22.

Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.

Tilghman SL, Sabnis G, Brodie AM.

Horm Mol Biol Clin Investig. 2010 Dec 1;3(1):357-66. doi: 10.1515/HMBCI.2010.042.

PMID:
25961207
23.

It's all about the talent.

Tilghman SM.

Mol Biol Cell. 2010 Nov 15;21(22):3823. doi: 10.1091/mbc.E10-05-0472. No abstract available.

24.

Glyceollin I enantiomers distinctly regulate ER-mediated gene expression.

Payton-Stewart F, Khupse RS, Boué SM, Elliott S, Zimmermann MC, Skripnikova EV, Ashe H, Tilghman SL, Beckman BS, Cleveland TE, McLachlan JA, Bhatnagar D, Wiese TE, Erhardt P, Burow ME.

Steroids. 2010 Dec;75(12):870-8. doi: 10.1016/j.steroids.2010.05.007. Epub 2010 May 21.

PMID:
20493896
25.

Environmental hormones: Multiple pathways for response may lead to multiple disease outcomes.

Tilghman SL, Nierth-Simpson EN, Wallace R, Burow ME, McLachlan JA.

Steroids. 2010 Aug-Sep;75(8-9):520-3. doi: 10.1016/j.steroids.2010.05.004. Epub 2010 May 11. Review.

PMID:
20466011
26.

Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy.

Zimmermann MC, Tilghman SL, Boué SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MH, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA, Wiese TE, Beckman BS, Burow ME.

J Pharmacol Exp Ther. 2010 Jan;332(1):35-45. doi: 10.1124/jpet.109.160382. Epub 2009 Oct 1.

27.

Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence.

Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME.

Breast Cancer Res Treat. 2010 Jun;121(2):293-300. doi: 10.1007/s10549-009-0458-2. Epub 2009 Jul 12.

28.

Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max).

Boué SM, Tilghman SL, Elliott S, Zimmerman MC, Williams KY, Payton-Stewart F, Miraflor AP, Howell MH, Shih BY, Carter-Wientjes CH, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, Burow ME.

Endocrinology. 2009 May;150(5):2446-53. doi: 10.1210/en.2008-1235. Epub 2008 Dec 30.

29.

Interview with president Shirley Tilghman (Princeton University).

Tilghman S.

Bioessays. 2008 May;30(5):480-6. doi: 10.1002/bies.20742. No abstract available.

PMID:
18404704
30.

Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.

Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A.

Cancer Res. 2006 Aug 1;66(15):7775-82.

31.
32.

Elongation of the Kcnq1ot1 transcript is required for genomic imprinting of neighboring genes.

Mancini-Dinardo D, Steele SJ, Levorse JM, Ingram RS, Tilghman SM.

Genes Dev. 2006 May 15;20(10):1268-82.

33.

Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the control of hepatic metabolism.

Hakimi P, Johnson MT, Yang J, Lepage DF, Conlon RA, Kalhan SC, Reshef L, Tilghman SM, Hanson RW.

Nutr Metab (Lond). 2005 Nov 21;2:33.

34.

Functional characterization of a novel Ku70/80 pause site at the H19/Igf2 imprinting control region.

Katz DJ, Beer MA, Levorse JM, Tilghman SM.

Mol Cell Biol. 2005 May;25(10):3855-63.

35.

Therapeutic observations in MCF-7 aromatase xenografts.

Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):884s-8s. Review.

36.

Education. Scientific teaching.

Handelsman J, Ebert-May D, Beichner R, Bruns P, Chang A, DeHaan R, Gentile J, Lauffer S, Stewart J, Tilghman SM, Wood WB.

Science. 2004 Apr 23;304(5670):521-2. No abstract available.

PMID:
15105480
37.

Functional characterization of a testis-specific DNA binding activity at the H19/Igf2 imprinting control region.

Bowman AB, Levorse JM, Ingram RS, Tilghman SM.

Mol Cell Biol. 2003 Nov;23(22):8345-51.

38.

Glyceroneogenesis and the triglyceride/fatty acid cycle.

Reshef L, Olswang Y, Cassuto H, Blum B, Croniger CM, Kalhan SC, Tilghman SM, Hanson RW.

J Biol Chem. 2003 Aug 15;278(33):30413-6. Epub 2003 Jun 4. Review. No abstract available.

39.
40.

Gatm, a creatine synthesis enzyme, is imprinted in mouse placenta.

Sandell LL, Guan XJ, Ingram R, Tilghman SM.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4622-7. Epub 2003 Apr 1.

41.

A differentially methylated region within the gene Kcnq1 functions as an imprinted promoter and silencer.

Mancini-DiNardo D, Steele SJ, Ingram RS, Tilghman SM.

Hum Mol Genet. 2003 Feb 1;12(3):283-94.

PMID:
12554682
42.

CTCF maintains differential methylation at the Igf2/H19 locus.

Schoenherr CJ, Levorse JM, Tilghman SM.

Nat Genet. 2003 Jan;33(1):66-9. Epub 2002 Dec 2.

PMID:
12461525
43.

Clock regulatory elements control cyclic expression of Lunatic fringe during somitogenesis.

Cole SE, Levorse JM, Tilghman SM, Vogt TF.

Dev Cell. 2002 Jul;3(1):75-84.

44.

Shirley Tilghman, PhD.

Tilghman S.

N J Med. 2002 Mar;99(3):14-20. No abstract available.

PMID:
11915194
45.

Genomic imprinting of a placental lactogen gene in Peromyscus.

Vrana PB, Matteson PG, Schmidt JV, Ingram RS, Joyce A, Prince KL, Dewey MJ, Tilghman SM.

Dev Genes Evol. 2001 Dec;211(11):523-32. Epub 2001 Nov 17.

PMID:
11862458
46.

A human H19 transgene exhibits impaired paternal-specific imprint acquisition and maintenance in mice.

Jones BK, Levorse J, Tilghman SM.

Hum Mol Genet. 2002 Feb 15;11(4):411-8.

PMID:
11854173
47.

Candidate genes required for embryonic development: a comparative analysis of distal mouse chromosome 14 and human chromosome 13q22.

Kurihara LJ, Semenova E, Miller W, Ingram RS, Guan XJ, Tilghman SM.

Genomics. 2002 Feb;79(2):154-61.

PMID:
11829485
48.

A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice.

Olswang Y, Cohen H, Papo O, Cassuto H, Croniger CM, Hakimi P, Tilghman SM, Hanson RW, Reshef L.

Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):625-30. Epub 2002 Jan 15.

49.

Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia.

Kurihara LJ, Kikuchi T, Wada K, Tilghman SM.

Hum Mol Genet. 2001 Sep 1;10(18):1963-70.

PMID:
11555633
50.

Disruption of an imprinted gene cluster by a targeted chromosomal translocation in mice.

Cleary MA, van Raamsdonk CD, Levorse J, Zheng B, Bradley A, Tilghman SM.

Nat Genet. 2001 Sep;29(1):78-82.

PMID:
11528397

Supplemental Content

Loading ...
Support Center